Breast Cancer Vaccine Using Neoantigens
Author Information
Author(s): Morisaki Takafumi, Kubo Makoto, Morisaki Shinji, Umebayashi Masayo, Tanaka Hiroto, Koya Norihiro, Nakagawa Shinichiro, Tsujimura Kenta, Yoshimura Sachiko, Kiyotani Kazuma, Nakamura Yusuke, Nakamura Masafumi, Morisaki Takashi
Primary Institution: Kyushu University and Fukuoka General Cancer Clinic
Hypothesis
Can HLA class II-restricted neoantigen-pulsed dendritic cell vaccines induce an immune response in breast cancer patients?
Conclusion
The study demonstrated the immunological efficacy of the HLA class II-restricted neoantigen peptide dendritic cell vaccine against breast cancer.
Supporting Evidence
- All patients showed an immune response to the vaccine.
- No relapses were reported in the five patients.
- T-cell responses were confirmed in all cases using ELISPOT analysis.
- TCR repertoire analysis showed increases in specific T-cell clones in two of three patients.
Takeaway
Researchers tested a new vaccine made from special proteins called neoantigens on five breast cancer patients, and it helped their immune systems fight the cancer without any reported relapses.
Methodology
The study involved whole exome and RNA sequencing of breast cancer tissues, neoantigen prediction, and administration of dendritic cells pulsed with synthesized HLA class II-restricted long peptides.
Limitations
The study had a small sample size and did not examine tumor heterogeneity.
Participant Demographics
Five patients with histologically confirmed breast cancer, including various subtypes and stages.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website